<qa>  What is the combination of Bevacizumab and Nintedanib being proposed toNintedanib has demonstrated anti-tumor activity in non-squamous non-small cell lung cancer, colorectal cancer, ovarian cancer, and renal cell cancer. The combination of Bevacizumab and Nintedanib are being proposed to target the tumors manipulation processes to generate alternate pathways for angiogenesis thus creating a potential benefit to delay tumor growth. 